SCHEMBL1703080

SCHEMBL1703080

Nc1n[nH]c2nccc(-c3ccc(NC(=O)Nc4cccc(Cl)c4)cc3)c12

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 18/20 0.74
KIT P10721 10/20 0.74
FLT3 P36888 10/20 0.74
PDGFRA P16234 2/20 0.67
VHL P40337 1/20 0.63
CSF1R P07333 6/20 0.63
LCK P06239 5/20 0.63
FLT1 P17948 5/20 0.63
FLT4 P35916 5/20 0.63
AURKB Q96GD4 4/20 0.63
LYN P07948 4/20 0.63
BLK P51451 4/20 0.63
PLK4 O00444 3/20 0.63
AURKA O14965 3/20 0.63
ROCK2 O75116 3/20 0.63
FGFR1 P11362 3/20 0.63
RPS6KB1 P23443 3/20 0.63
CSNK1D P48730 3/20 0.63
RPS6KA3 P51812 3/20 0.63
STK3 Q13188 3/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2818366 0.88 KDR (0.69) KDRKITFLT3PDGFRACSF1R
SCHEMBL1702950 0.88 KDR (0.74) KDRKITFLT3PDGFRACSF1R
SCHEMBL1703109 0.87 KDR (0.74) KDRKITFLT3PDGFRACSF1R
SCHEMBL27974282 0.87 KDR (0.66) KDRKITFLT3PDGFRACSF1R
SCHEMBL421753 0.85 KDR (1.00) KDRKITFLT3VHLCSF1R
SCHEMBL1702977 0.85 KDR (0.75) KDRKITFLT3PDGFRACSF1R
SCHEMBL2237890 0.85 KDR (0.75) KDRKITFLT3PDGFRACSF1R
SCHEMBL1702941 0.85 KDR (0.75) KDRKITFLT3PDGFRACSF1R
SCHEMBL1703314 0.84 KDR (1.00) KDRKITFLT3PDGFRAVHL
SCHEMBL2235206 0.84 KDR (0.62) KDRKITFLT3PDGFRACSF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1807424-B1 NOVEL KINASE INHIBITORS ABBOTT LAB (US) 2012-04-18 EP claimed
US-20060178378-A1 Novel kinase inhibitors ABBVIE INC. 2006-08-10 US claimed
US-7812166-B2 Kinase inhibitors ABBOTT LABORATORIES (US) 2010-10-12 US disclosed
EP-1807424-A2 NOVEL KINASE INHIBITORS ABBOTT LABORATORIES (US) 2007-07-18 EP disclosed
US-20060178378-A1 Novel kinase inhibitors ABBVIE INC. 2006-08-10 US disclosed
WO-2006050109-A2 NOVEL KINASE INHIBITORS ABBOTT LABORATORIES (US) 2006-05-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060178378-A1 Novel kinase inhibitors ABL1, MAP3K19, MAP3K20 KDR 434/4885KIT 426/4885FLT3 79/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.